TARGETING CDK9-DEPENDENT SUPER-ENHANCER ADDICTION IN IDIOPATHIC PULMONARY FIBROSIS WITH ORALLY AVAILABLE SMALL-MOLECULE INHIBITORS

$304,931FY2021Department of the ArmyDOD

Oncolexis Therapeutics Inc.

Investigators